Ann Dermatol.
2007 Dec;19(4):173-175. 10.5021/ad.2007.19.4.173.
Gefitinib-induced Paronychia Teated by Cyosurgery
- Affiliations
-
- 1Department of Dermatology, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Korea. jmyang@smc.samsung.co.kr
- 2Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, Korea.
- KMID: 2156345
- DOI: http://doi.org/10.5021/ad.2007.19.4.173
Abstract
- Gefitinib (Iressa, ZD1839) is one of the epidermal growth factor receptor (EGFR) inhibitors approved for the treatment of advanced non-small cell lung cancer. The cutaneous reactions to EGFR inhibitors manifest as a follicular eruption, nail toxicity, xerosis, or desquamation. These adverse events, if not properly managed, can interfere with activities of daily living. We report a case of paronychia induced by gefitinib successfully treated with cryosurgery which is a simple and safe treatment.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Alitretinoin Treatment for Gefitinib-Induced Paronychia
- Cutaneous Adverse Reactions Induced by Gefitinib (Iressa) in Lung Cancer Patients
- The Effectiveness of Gefitinib on Spinal Metastases of Lung Cancer: Report of Two Cases
- Cutaneous Adverse Reactions Associated with Epidermal Growth Factor Receptor Inhibitors
- Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
